THRX—(-69%/AH)—discontinues lead program due to toxicity: https://www.prnewswire.com/news-releases/theseus-pharmaceuticals-to-discontinue-enrollment-in-phase-12-study-and-terminate-development-of-the-630-in-patients-with-gist-301877076.html